Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.50 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.50 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913941 | 0.87 | PDE10A (0.61) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL3028085 | 0.86 | PDE10A (0.46) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL1262322 | 0.83 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL6798820 | 0.83 | CYSLTR2 (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL3100809 | 0.83 | CYSLTR1 (0.53) | PDE10ACYSLTR2CYSLTR1CYP1A2NCF1 | |
| SCHEMBL2334595 | 0.81 | CYSLTR2 (0.52) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL296473 | 0.79 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL177540 | 0.79 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL4846265 | 0.79 | PDE10A (0.50) | PDE10ACYSLTR2CYSLTR1CYP1A2CYP3A4 | |
| SCHEMBL725176 | 0.79 | PDE10A (0.54) | PDE10ACYSLTR2CYSLTR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | PDE10A 4322/4885CYSLTR2 1215/4885CYSLTR1 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.